Does orlistat cause acute kidney injury?

Beyea, Michael M.; Garg, Amit X.; Weir, Matthew A.

doi:10.1177/2042098611429985

Cited by 18 publications

(8 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Predictably, orlistat caused gastrointestinal side effects but these were not severe enough to result in participant withdrawal. No patients developed hyperoxaluria, although this remains a concern given the fat malabsorption caused by orlistat (one of the same mechanisms implicated in the enteric hyperoxaluria accompanying RYGB) (139,140).…”

Section: What Is the Role Of Metabolic Surgery In People With End-stamentioning

confidence: 99%

Metabolic Surgery to Treat Obesity in Diabetic Kidney Disease, Chronic Kidney Disease, and End-Stage Kidney Disease; What Are the Unanswered Questions?

et al. 2020

View full text Add to dashboard Cite

Obesity is a major factor in contemporary clinical practice in nephrology. Obesity accelerates the progression of both diabetic and non-diabetic chronic kidney disease and, in renal transplantation, both recipient and donor obesity increase the risk of allograft complications. Obesity is thus a major driver of renal disease progression and a barrier to deceased and living donor kidney transplantation. Large observational studies have highlighted that metabolic surgery reduces the incidence of albuminuria, slows chronic kidney disease progression, and reduces the incidence of end-stage kidney disease over extended follow-up in people with and without type 2 diabetes. The surgical treatment of obesity and its metabolic sequelae has therefore the potential to improve management of diabetic and non-diabetic chronic kidney disease and aid in the slowing of renal decline toward end-stage kidney disease. In the context of patients with end-stage kidney disease, although complications of metabolic surgery are higher, absolute event rates are low and it remains a safe intervention in this population. Pre-transplant metabolic surgery increases access to kidney transplantation in people with obesity and end-stage kidney disease. Metabolic surgery also improves management of metabolic complications post-kidney transplantation, including new-onset diabetes. Procedure selection may be critical to mitigate the risks of oxalate nephropathy and disruption to immunosuppressant pharmacokinetics. Metabolic surgery may also have a role in the treatment of donor obesity, which could increase the living kidney donor pool with potential downstream impact on kidney paired exchange programmes. The present paper provides a comprehensive coverage of the literature concerning renal outcomes in clinical studies of metabolic surgery and integrates findings from relevant mechanistic pre-clinical studies. In so doing the key unanswered questions for the field are brought to the fore for discussion.

show abstract

Section: What Is the Role Of Metabolic Surgery In People With End-stamentioning

confidence: 99%

Metabolic Surgery to Treat Obesity in Diabetic Kidney Disease, Chronic Kidney Disease, and End-Stage Kidney Disease; What Are the Unanswered Questions?

et al. 2020

View full text Add to dashboard Cite

show abstract

“…First, orlistat use in patients with chronic disease is contraindicated because of its association with acute kidney injury and chronic kidney disease due to increased absorption of oxalate and the risk of nephrocalcinosis, inflammation and kidney fibrosis as a result [26][27][28]. Moreover, post-transplant drug interaction, particularly with cyclosporin, results in reducing their bioavailability and limits its use [29]. Secondly, sibutramine was withdrawn from the obesity treatment due to unacceptable increased cardiovascular risk [30].…”

Section: Discussionmentioning

confidence: 99%

Obesity in work-up of kidney transplant candidates – review of clinical practice guidelines.

Dobrzycka¹,

Spychalski²,

Łącka³

et al. 2020

Eur J Trans Clin Med

View full text Add to dashboard Cite

show abstract

“…Its adverse effects include abdominal pain, steatorrhea, and fecal urgency/incontinence and have also been implicated in kidney damage. Ultimately, it was designed for weight loss rather than diabetes, and as such, it may be used as an adjunct therapy to other diabetic drugs rather than as a first-line treatment [31, 32].…”

Section: Diabetes Medicationsmentioning

confidence: 99%

Safety and Mode of Action of Diabetes Medications in comparison with 5-Aminolevulinic Acid (5-ALA)

Rehani

Iftikhar

Nakajima

et al. 2019

Journal of Diabetes Research

View full text Add to dashboard Cite

5-Aminolevulinic acid (5-ALA) is a delta amino acid naturally present in every living cell of the human body. 5-ALA is produced in the mitochondria as the first product of the porphyrin synthesis pathway and composes heme; exogenously supplemented 5-ALA helps in upregulating mitochondrial functions. Mitochondrial dysfunction has been associated with the pathophysiology of diabetes mellitus. Thus, in this review, we evaluate the mechanisms of action and adverse effects of common medications used to treat type 2 diabetes mellitus as well as 5-ALA including its mechanism and possible use in diabetes management.

show abstract

Does orlistat cause acute kidney injury?

Cited by 18 publications

References 40 publications

Metabolic Surgery to Treat Obesity in Diabetic Kidney Disease, Chronic Kidney Disease, and End-Stage Kidney Disease; What Are the Unanswered Questions?

Metabolic Surgery to Treat Obesity in Diabetic Kidney Disease, Chronic Kidney Disease, and End-Stage Kidney Disease; What Are the Unanswered Questions?

Obesity in work-up of kidney transplant candidates – review of clinical practice guidelines.

Safety and Mode of Action of Diabetes Medications in comparison with 5-Aminolevulinic Acid (5-ALA)

Contact Info

Product

Resources

About